^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

solitomab (AMG 110)

i
Other names: AMG 110, MT110, AMG-110
Associations
Trials
Company:
Amgen
Drug class:
CD3 agonist, EPCAM inhibitor
Related drugs:
Associations
Trials
over1year
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells. (PubMed, Oncoimmunology)
In contrast, analogous treatment with equimolar amounts of EpCAM/CD3-directed bispecific T-cell engager solitomab resulted in a massive release of IFNγ, a feature commonly associated with adverse cytokine-release syndrome. Combinatorial treatment with EpCAM-ReTARG and EGFR-ReTARG strongly potentiated selective cancer cell elimination owing to the concerted action of the corresponding cognate anti-CMV CD8 T cell clones. In conclusion, ReTARG fusion proteins may be useful as an alternative or complementary form of targeted cancer immunotherapy for 'cold' solid cancers.
Journal
|
EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • EPCAM (Epithelial cell adhesion molecule)
|
EPCAM expression
|
solitomab (AMG 110)
over3years
EpCAM expression in esophageal cancer and its correlation with immunotherapy of solitomab. (PubMed, J Thorac Dis)
Different concentrations of nanoparticle albumin-bound paclitaxel (Nab-PTX) and cisplatin were used to treat the two groups of cells and compare their drug resistance. Further, EC Eca109 cell spheres have a high expression level of EpCAM, and EpCAM may be one of the markers of EC stem cells. Therefore, EpCAM could be used as a potential molecular target of immunotherapy for EC, and solitomab may become an effective immunotherapeutic drug for chemotherapy-resistant EC cells.
Journal • IO biomarker
|
EPCAM (Epithelial cell adhesion molecule)
|
EPCAM expression
|
cisplatin • albumin-bound paclitaxel • solitomab (AMG 110)
4years
[VIRTUAL] HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (SITC 2020)
For example, clinical testing of solitomab, an EpCAM-targeting T cell engager, resulted in severe dose-limiting toxicities, including elevated liver transaminases, hyperbilirubinemia, and diarrhea. Conclusions HPN601 is a conditionally active EpCAM-targeting T cell engager with a ten-fold improved therapeutic window compared to a constitutively active EpCAM-targeting T cell engager. An EpCAM-specific T cell engager with an improved safety profile could address unmet needs in many solid tumors and demonstrate the feasibility of using conditionally active T cell engagers to target more solid tumor antigens.
Clinical
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • EPCAM (Epithelial cell adhesion molecule) • IL10 (Interleukin 10)
|
EPCAM expression
|
HPN601 • solitomab (AMG 110)
4years
[VIRTUAL] HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors (SITC 2020)
For example, clinical testing of solitomab, an EpCAM-targeting T cell engager, resulted in severe dose-limiting toxicities, including elevated liver transaminases, hyperbilirubinemia, and diarrhea. Conclusions HPN601 is a conditionally active EpCAM-targeting T cell engager with a ten-fold improved therapeutic window compared to a constitutively active EpCAM-targeting T cell engager. An EpCAM-specific T cell engager with an improved safety profile could address unmet needs in many solid tumors and demonstrate the feasibility of using conditionally active T cell engagers to target more solid tumor antigens.
Clinical
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • EPCAM (Epithelial cell adhesion molecule) • IL10 (Interleukin 10)
|
EPCAM expression
|
HPN601 • solitomab (AMG 110)
over4years
[VIRTUAL] Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells (AACR-II 2020)
However, clinical trials with anti-EpCAM antibodies (ING-1, 3622W94) and bispecific T cell engager antibodies (Solitomab) have shown significant dose-limiting toxicities, resulting in very limited clinical responses... Low-affinity EpCAM targeting CAR T cells demonstrated durable antitumor activity against various tumor models in vivo. To enhance safety and therapeutic efficacy, micromolar affinity anti-EpCAM CAR T cells are currently being evaluated to limit cell killing to EpCAM-positive tumor cells while sparing normal cells with basal levels of EpCAM expression.
CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • EPCAM (Epithelial cell adhesion molecule) • CSF2 (Colony stimulating factor 2)
|
EPCAM expression
|
solitomab (AMG 110)